Literature DB >> 389035

Sensitivity of group A streptococci to antibiotics. Prevalence of resistance to erythromycin in Japan.

S Maruyama, H Yoshioka, K Fujita, M Takimoto, Y Satake.   

Abstract

More than 60% of all strains of group A streptococci isolated during the period from 1974 to 1975 from children with streptococcal infections in Hokkaido district, Japan, were highly resistant to erythromycin. These strains were found to be multiply resistant to lincomycin hydrochloride monohydrate, chloramphenicol, and tetracycline, and were exclusively type 12 by T-protein typing. The clinical symptoms produced by these organisms were rather mild, responded to penicillin well, and were rarely complicated with glomerulonephritis. The high prevalence of resistant group A streptococci was nationwide, which may have been related to recent excessive use of erythromycin and other macrolide antibiotics. Erythromycin can no longer be considered the drug of choice in the management of streptococcal infections in Japan. This suggests that a periodic surveillance of antibiotic sensitivity of streptococcal isolates may be necessary in other countries in which macrolide antibiotics are frequently prescribed.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 389035     DOI: 10.1001/archpedi.1979.02130110051007

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  37 in total

1.  Unusual occurrence of M type 77, antibiotic-resistant group A streptococci in southern Sweden.

Authors:  A Jasir; A Tanna; A Efstratiou; C Schalén
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

2.  Prevalence and mechanisms of macrolide resistance in clinical isolates of group A streptococci from Ontario, Canada.

Authors:  J C De Azavedo; R H Yeung; D J Bast; C L Duncan; S B Borgia; D E Low
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

3.  High rate of tetracycline resistance in Streptococcus pyogenes in Iran: an epidemiological study.

Authors:  A Jasir; A Tanna; A Noorani; A Mirsalehian; A Efstratiou; C Schalen
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

4.  Azithromycin versus Penicillin in Acute Group A Streptococcal Tonsillopharyngitis.

Authors:  Itzhak Brook
Journal:  Curr Infect Dis Rep       Date:  2003-06       Impact factor: 3.725

5.  Dissemination of emm28 erythromycin-, clindamycin- and bacitracin-resistant Streptococcus pyogenes in Spain.

Authors:  E Perez-Trallero; C Garcia; B Orden; J M Marimon; M Montes
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-01-08       Impact factor: 3.267

6.  Evolution and global dissemination of macrolide-resistant group A streptococci.

Authors:  D Ashley Robinson; Joyce A Sutcliffe; Wezenet Tewodros; Anand Manoharan; Debra E Bessen
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

7.  Antimicrobial resistance of 914 beta-hemolytic streptococci isolated from pharyngeal swabs in Spain: results of a 1-year (1996-1997) multicenter surveillance study. The Spanish Surveillance Group for Respiratory Pathogens.

Authors:  F Baquero; J A García-Rodríguez; J G de Lomas; L Aguilar
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

8.  Serotyping and susceptibility to macrolides and other antimicrobial drugs of Streptococcus pyogenes isolated from patients with invasive diseases in southern Israel.

Authors:  I Weiss; Z Gorodnitzky; Z Korenman; P Yagupsky
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-01       Impact factor: 3.267

9.  The extended microbiology of group A streptococcal pharyngitis. Observations during a double-blind controlled study of cephalexin twice versus four-times daily.

Authors:  M M Tarpay; S Chartrand; M Marks; A Cox
Journal:  Infection       Date:  1984 May-Jun       Impact factor: 3.553

Review 10.  Addressing the burden of group A streptococcal disease in India.

Authors:  Anita Shet; Edward Kaplan
Journal:  Indian J Pediatr       Date:  2004-01       Impact factor: 1.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.